PR News Wire (Free subscription) | 05/15/2008
NEW YORK, May 14 /PRNewswire/ -- The F.A.C.E. Diabetes campaign is traveling across the country to help connect and empower African-Americans to take a stance against diabetes. Listen to this report from Eli Lilly and Company at: Registered journalists can access video, audio, text, graphics and photos for free and unrestricted use at . 05NY08-0078
Bharat Book's Research Blog (Free subscription) | 05/13/2008
The Eli Lilly and Company Strategic Analysis Profile is a comprehensive profile of the company including both quantitative and qualitative research. The report examines the Eli Lilly and Company's business structure and operations, history and products, and provides an analysis of its key revenue lines. The profile provides strategic insight on the company by examining [...]
nitesh | 05/14/2008
The Eli Lilly and Company Strategic Analysis Profile is a comprehensive profile of the company including both quantitative and qualitative research. The report examines the Eli Lilly and Company's business structure and operations, history and products, and provides an analysis of its key revenue lines. The profile provides strategic insight on the company by examining its strategy,
Medical News Today (Free subscription) | 05/14/2008
Eli Lilly and Company announced the scaling-up of an existing partnership with the World Medical Association (WMA) by providing a grant of $998,773 to expand training courses for physicians on multi-drug resistant tuberculosis (MDR-TB). Tuberculosis (TB) is a preventable disease that kills close to two million people every year and infects an estimated nine million more.
PR News Wire (Free subscription) | 05/15/2008
Toronto Stock Exchange Symbol: MS EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the...
Red Orbit (Free subscription) | yesterday
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (Pemetrexed for Injection)INDIANAPOLIS, May 15 /PRNewswire-FirstCall/ -- Lung cancer patients whose histology is factored into treatment decisions may fare better as a result, according to data from a pivotal non-small cell lung cancer (NSCLC) clinical trial. Data from the trial, which involved ...
Red Orbit (Free subscription) | 05/15/2008
Mr. Nicholson joins Pfizer from Eli Lilly and Company, where he spent more than 10 years as Executive Director of the U.S. Oncology Business Unit and subsequently in an expanded role as Global Oncology Platform Leader. In the latter role, Mr. Nicholson was responsible for the global Oncology franchise, including the Oncology therapeutic area strategy, portfolio management, Phase II/III development,...
Business Wire (Free subscription) | 05/15/2008
Mr. Nicholson joins Pfizer from Eli Lilly and Company, where he spent more than 10 years as Executive Director of the U.S. Oncology Business Unit and subsequently in an expanded role as Global Oncology Platform Leader. In the latter role, Mr. Nicholson was responsible for the global Oncology franchise, including the Oncology therapeutic area strategy, portfolio management, Phase II/III development,...
Red Orbit (Free subscription) | 05/12/2008
INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today completion of the final phase of its $1 billion effort to further strengthen the company's biotechnology research and development capabilities.
PR News Wire (Free subscription) | 05/14/2008
INDIANAPOLIS, May 14 /PRNewswire-FirstCall/ -- Thousands of Eli Lilly and Company employees in nearly 50 nations are rolling up their sleeves today to help address local community needs in celebration of Lilly's first-ever Global Day of Service, possibly the largest corporate volunteer initiative to ever take place on one day. Beginning at sunrise in New Zealand, Lilly employees from Algeria to Venezuela...
thoughts about health (Free subscription) | 05/14/2008
View this email as a Web page Please add news@healthcarefinancenews.com to your Safe Sender list HOME | SUBSCRIBE | RESOURCE CENTRAL | ADVERTISE | ABOUT US | VIEW ONLINE Daily news by email for healthcare financial managers May 14, 2008 Senators push drug payment transparency, get nod from industry Sen. Chuck Grassley (R-Iowa), ranking member of the Senate Committee on Finance, praised ...
The Earth Times Online Newspaper (Free subscription) | 05/13/2008
... drug discovery company, from its founding in July 2000 through its $315 million acquisition by Eli Lilly and Company in April 2007. Before Hypnion, Mr. Dee spent three years as a "turn- around" CEO, specializing in reviving under-performing biotechnology companies including Genta, Inc. Prior to his move into biotechnology, Mr. Dee spent several years as a senior management consultant at...
Antibody Technologies (Free subscription) | 05/13/2008
... Drug More... • Mylan Is Looking For A Buyer For Its Emergency-Treatments Business More... • 335 Eli Lilly and Company ( LLY ) Employees Accept Buyout Offer From Drug Maker, Jobs Will End June 30 More... • SGX Pharmaceuticals, Inc. ( SGXP ) Discontinued Development of SGX523; Announces First Quarter Financial Results More... • Bristol-Myers Squibb Company ( BMY ) and KAI Pharmaceuticals,...
Medical News Today (Free subscription) | 05/10/2008
Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.
PR News Wire (Free subscription) | 05/12/2008
- Adds significant strategic biotech business experience - CAMBRIDGE, Mass., May 12 /PRNewswire-FirstCall/ -. Verenium Corporation (Nasdaq: ), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, today announced the appointment of John F. Dee to its Board of Directors. The Company also announced that Geoffrey Hazlewood, Ph.D., Senior Vice President...
